Gain Therapeutics Inc Total Liabilities
Gain Therapeutics Inc total liabilities. Based on the latest financial reports, Gain Therapeutics Inc (GANX) has total liabilities worth $4.73 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GANX financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Gain Therapeutics Inc (2018–2025)
Total liabilities of Gain Therapeutics Inc from 2018 to 2025. This chart illustrates how Gain Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Gain Therapeutics Inc (GANX) long-term investment share to see how much of total assets are deployed in long-term investments.
Gain Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Gain Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TNR Gold Corp.
V:TNR
|
Canada | CA$77.62K |
|
First Breach Inc. Common Stock
NASDAQ:FBDT
|
USA | $16.25 Million |
|
Sekar Bumi Tbk
JK:SKBM
|
Indonesia | Rp1.07 Trillion |
|
FELIX Gold Ltd
AU:FXG
|
Australia | AU$1.22 Million |
|
EnerSyn Global Inc.
NASDAQ:ESYN
|
USA | $1.71 Million |
|
Yarrow Bioscience Inc
NASDAQ:YARW
|
USA | $1.24 Million |
|
SM Culture & Contents Co. Ltd
KQ:048550
|
Korea | ₩134.83 Billion |
|
LABIANA HEALTH S.A.EO-10
F:8RK
|
Germany | €52.79 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Gain Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Gain Therapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Gain Therapeutics Inc Total Liabilities Ratios Explained
Gain Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gain Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gain Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Gain Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.25 Million | -11.08% |
| 2024-12-31 | $4.78 Million | -20.67% |
| 2023-12-31 | $6.03 Million | +15.54% |
| 2022-12-31 | $5.22 Million | +25.25% |
| 2021-12-31 | $4.17 Million | +22.49% |
| 2020-12-31 | $3.40 Million | +206.48% |
| 2019-12-31 | $1.11 Million | -37.01% |
| 2018-12-31 | $1.76 Million | -- |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and t… Read more